Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.
暂无分享,去创建一个
[1] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Michael Gaziano,et al. Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs , 2003, Circulation.
[3] Andreas Hoeft,et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.
[4] Celecoxib Does Not Affect the Antiplatelet Activity of Aspirin in Healthy Volunteers , 2002, Journal of clinical pharmacology.
[5] G. Rosen,et al. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. , 1989, Biochemical and biophysical research communications.
[6] Tom S. Price,et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. , 2006, Gastroenterology.
[7] T. Hedner,et al. Nabumetone , 2012, Drugs.
[8] D. Fitzgerald,et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. , 2000, Circulation.
[9] Gerd Geisslinger,et al. Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] G. FitzGerald,et al. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. , 2005, The Journal of clinical investigation.
[11] C. Cerletti,et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. , 1999, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[12] Mark A. Magnuson,et al. Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor , 1999, Nature Medicine.
[13] M. Weatherall,et al. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. , 2005, The New Zealand medical journal.
[14] S. Narumiya,et al. Roles of Prostaglandin I2 and Thromboxane A2 in Cardiac Ischemia-Reperfusion Injury: A Study Using Mice Lacking Their Respective Receptors , 2001, Circulation.
[15] P. Duke,et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.
[16] R. Kurumbail,et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.
[17] J. Kent,et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis , 2002, European journal of gastroenterology & hepatology.
[18] R. Stafford,et al. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.
[19] V. Strand,et al. Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis , 2004, American journal of therapeutics.
[20] W. Ray,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease☆ , 2003 .
[21] T. Macdonald,et al. Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.
[22] C Michael Stein,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.
[23] J. Richards,et al. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. Induction in vivo and in vitro. , 1992, The Journal of biological chemistry.
[24] Sebastian Schneeweiss,et al. Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.
[25] H. Krumholz,et al. The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype? , 2004, Journal of the American College of Cardiology.
[26] T. Schnitzer,et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.
[27] Carol Coupland,et al. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.
[28] J. Wallace,et al. Emerging roles for cyclooxygenase‐2 in gastrointestinal mucosal defense , 2005, British journal of pharmacology.
[29] Marc A Pfeffer,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.
[30] M. Hudson,et al. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. , 2005, The Journal of rheumatology.
[31] David A Jones,et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.
[32] C. Cannon,et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. , 2006, American heart journal.
[33] J. Oates,et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Fries,et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[35] E. Ricciotti,et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. , 2005, Journal of the American College of Cardiology.
[36] J. Maclouf,et al. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays. , 1995, Biochimica et biophysica acta.
[37] H. Krum,et al. To the heart of the matter: coxibs, smoking, and cardiovascular risk. , 2005, Circulation.
[38] C. Patrono,et al. Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.
[39] G. FitzGerald,et al. Genetic and pharmacological analysis of prostanoid receptor function. , 2001, The Journal of clinical investigation.
[40] Robert Riddell,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[41] B. Koller,et al. E-Prostanoid-3 Receptors Mediate the Proinflammatory Actions of Prostaglandin E2 in Acute Cutaneous Inflammation1 , 2004, The Journal of Immunology.
[42] A. Sollevi,et al. Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. , 1985, Circulation.
[43] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[44] D. Fitzgerald,et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.
[45] H. Prast,et al. Modulation of histamine release in the hypothalamus by nitric oxide , 1997, Inflammation Research.
[46] J. Chow,et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.
[47] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[48] H R Herschman,et al. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. , 1992, The Journal of biological chemistry.
[49] H. Krum,et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. , 2005, Archives of internal medicine.
[50] L. Crofford,et al. Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries , 2001, Circulation.
[51] Tianxin Yang,et al. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. , 2005, American journal of physiology. Renal physiology.
[52] H. Guess,et al. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. , 2003, The Journal of rheumatology.
[53] P. E. Cesare,et al. Disease-Modifying Therapies for Osteoarthritis , 2005, Drugs & aging.
[54] B. Gertz,et al. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers , 2000, Journal of clinical pharmacology.
[55] S. Hernández-Díaz,et al. Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs , 2001, Epidemiology.
[56] B. Psaty,et al. Parecoxib, valdecoxib, and cardiovascular risk. , 2005, Circulation.
[57] Shuh Narumiya,et al. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[58] K. Schrör,et al. Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery , 2003, Circulation.
[59] G. FitzGerald,et al. Measurement of thromboxane metabolites by gas chromatography-mass spectrometry. , 1990, Methods in enzymology.
[60] J. Mcgiff,et al. Renal arterial 20-hydroxyeicosatetraenoic acid levels: regulation by cyclooxygenase. , 2003, American journal of physiology. Renal physiology.
[61] J. Avorn,et al. Relationship Between COX-2 Specific Inhibitors and Hypertension , 2004, Hypertension.
[62] K. Seibert,et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. , 1990, The Journal of clinical investigation.
[63] T. Grosser,et al. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.
[64] D. Graham,et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.
[65] E. Tremoli,et al. Biological effects of coronary surgery: role of surgical trauma and CPB. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[66] J. Vane,et al. HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATION , 1977, The Lancet.
[67] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.
[68] M. Stampfer,et al. Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women , 2005, Hypertension.
[69] D. Rader,et al. COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice , 2004, Science.
[70] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[71] J. Oates,et al. Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.
[72] A. K. Pedersen,et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.
[73] P. Loll,et al. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.
[74] C. Reynolds,et al. Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid , 2004, Clinical pharmacokinetics.
[75] J. Bolognese,et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.
[76] G. FitzGerald,et al. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. , 1983, Circulation.
[77] S. E. Brodie. New York, New York, USA , 1996 .
[78] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors☆ , 2002 .
[79] B. Hinz,et al. Selective cyclooxygenase‐2 inhibitors: similarities and differences , 2004, Scandinavian journal of rheumatology.
[80] M. Gimbrone,et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[81] G. FitzGerald,et al. The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.
[82] T. Hla,et al. Differential recovery of prostacyclin synthesis in cultured vascular endothelial vs. smooth muscle cells after inactivation of cyclooxygenase with aspirin. , 1989, Prostaglandins, leukotrienes, and essential fatty acids.
[83] M. Farkouh,et al. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics , 2004, Alimentary pharmacology & therapeutics.
[84] G. Triadafilopoulos,et al. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. , 2004, The American journal of medicine.
[85] Peter Jüni,et al. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.
[86] G. FitzGerald,et al. Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. , 1985, Circulation.
[87] P. Conzen,et al. Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo , 2004, Circulation.
[88] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[89] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[90] G. FitzGerald,et al. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.
[91] V. Winn,et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[92] E. Topol,et al. A coxib a day won't keep the doctor away , 2004, The Lancet.
[93] M. Reilly,et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.
[94] R. Garavito,et al. Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.
[95] G. FitzGerald,et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. , 2000, The Journal of clinical investigation.
[96] J. Bolognese,et al. Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen , 1999, Alimentary pharmacology & therapeutics.
[97] J. Fischer,et al. Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2–Derived Prostaglandins , 2004, Circulation research.
[98] P. Libby,et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.
[99] G. FitzGerald,et al. Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib , 2005, PLoS medicine.
[100] J A Lewis,et al. Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.
[101] M. Reilly,et al. Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.
[102] A. Maguire,et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population , 2004, Circulation.
[103] S. Narumiya,et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice , 2004 .
[104] K. Seibert,et al. Mediation of inflammation by cyclooxygenase-2. , 1995, Agents and actions. Supplements.
[105] D. Fitzgerald,et al. Intravascular Thrombosis After Hypoxia-Induced Pulmonary Hypertension: Regulation by Cyclooxygenase-2 , 2004, Circulation.
[106] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[107] N. Maskrey,et al. NSAIDs, gastroprotection and cyclo‐oxygenase‐II‐selective inhibitors * , 2003, Alimentary pharmacology & therapeutics.
[108] G. FitzGerald. Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.
[109] J. Morrow,et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. , 2002, The Journal of clinical investigation.
[110] C. Patrono,et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings , 1998, Clinical pharmacology and therapeutics.
[111] H. Weiss,et al. Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.
[112] Garret A. FitzGerald,et al. COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.
[113] C. Patrono,et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1997, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[114] R. D. Rudic,et al. COX-2–Derived Prostacyclin Modulates Vascular Remodeling , 2005, Circulation research.
[115] T. Hla,et al. Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[116] Marta L. Capone,et al. Clinical pharmacology of novel selective COX-2 inhibitors. , 2004, Current pharmaceutical design.
[117] C. Funk. Leukotriene modifiers as potential therapeutics for cardiovascular disease , 2005, Nature Reviews Drug Discovery.